key: cord-0997210-tynn8700 authors: Aboueshia, Mohamed; Hussein, Mohammad Hosny; Attia, Abdallah S; Swinford, Aubrey; Miller, Peter; Omar, Mahmoud; Toraih, Eman Ali; Saba, Nakhle; Safah, Hana; Duchesne, Juan; Kandil, Emad title: Cancer and COVID-19: analysis of patient outcomes date: 2021-07-15 journal: Future oncology DOI: 10.2217/fon-2021-0121 sha: 3114420bfc07e18049a9e7045b42c4de7a30bb81 doc_id: 997210 cord_uid: tynn8700 Background: We sought to investigate the outcomes associated with COVID-19 disease in cancer patients. Methods: We conducted a retrospective cohort study of laboratory-confirmed COVID-19 patients. Results: Of the 206 patients included, 57 had at least one preexisting malignancy. Cancer patients were older than noncancer patients. Of the 185 discharged cases, cancer patients had a significantly higher frequency of unplanned reintubation (7.1% vs 0.9%, p < 0.049), and required longer hospital stay (8.58 ± 6.50 days versus 12.83 ± 11.44 days, p < 0.002). Regression analysis revealed that obesity and active smoking were associated with an increased risk of mortality. Conclusion: Outcomes in COVID-19 appear to be driven by obesity as well as active smoking, with no difference in mortality between cancer and noncancer patients. conditions have consistently been shown to have a higher risk of severe COVID-19 illness and adverse outcomes [2] . This gives rise to the ethical dilemma physicians face, especially with the shortage in resources the health system has been exposed to during the pandemic and the scarcity of data available in the literature on how to manage these patients [3, 4] . Another ethical consideration that should be taken into account is the stress the cancer patients experience if their treatment was postponed [5] . Early evidence from China suggested increased risk of COVID-19 and adverse events in cancer patients; however, the evidence supporting these conclusions was lacking [6, 7] . Later meta-analysis of studies from China and Italy showed an increased risk for COVID-19 and adverse events in cancer patients compared with the general population, although the study authors acknowledged that experts should only cautiously extrapolate from the study results [8] . Studies in the USA related to COVID-19 and cancer are ongoing, but data from the New York State Department of Health shows that as of 14 August 2020, 7.6% of deaths attributable to COVID-19 were in patients with cancer [9] . Cumulatively, these data suggest that cancer patients are at greater risk for mortality and adverse outcomes from COVID-19, but interpretation should be made cautiously. Epidemiological data within the US remain limited, and cancer patients are a diverse cohort. This article attempts to study the relationship between cancer and severe COVID-19 illness with adverse outcomes. We hope this will contribute to the literature available to help physicians better manage the treatment of cancer patients during the pandemic. Study data were collected and managed using REDCap electronic data capture tools hosted at Tulane Medical Center. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing an intuitive interface for validated data capture and audit trails for tracking data manipulation and export procedures [10] . Adult hospitalized patients were collected during the period between 27 February and 27 April 2020. COVID-19 testing for patients was done using RT-PCR through the Louisiana Office of Public Health (OPH) Laboratory. Institutional review board (IRB) approval was obtained. Cancer patients were divided into patients receiving treatment as active cancer and patients in remission with nonactive cancer. Demographics, clinical presentation, comorbidities, laboratory values on admission, complications and outcomes were collected. PaO 2 /FIO 2 ratio was estimated as the ratio of arterial oxygen partial pressure (PaO 2 in mm Hg) to fractional inspired oxygen [11] . The neutrophil-lymphocyte ratio was determined an indicator for poor outcome [12] . Two scoring systems were used for severity assessment: first, the CURB-65 score -confusion status, blood urea nitrogen level >19 mg/dl (>7 mmol/l), respiratory rate ≥30, blood pressure (systolic <90 mm Hg or diastolic ≤60 mm Hg) and age ≥65 years [13] ; second, the Quick Sequential Organ Failure Assessment (qSOFA) score based on Glasgow Coma Score <15, respiratory rate ≥22 and systolic blood pressure ≤100 [14] . Comparisons between cancer and noncancer groups and between active and nonactive cancer cohorts were performed. The primary outcome of concern was in-hospital mortality. Secondary outcomes were risk of intensive care unit (ICU) admission, risk of endotracheal intubation, duration of mechanical ventilation and length of hospital stay. Data management was carried out using SAS 9.4 (SAS Institute Inc., 2013, NC, USA), and statistical analysis was performed using STATA 16.0 (StataCorp., 2019, TX, USA) and SPSS 26.0 (SPSS, Inc., IL, USA). Quantitative data were described as mean and standard deviation (SD), and binary variables were presented as frequencies and percentages. Chi-square or Fisher's exact tests were applied to test the differences in categorical variables, and Student's t-and Mann-Whitney U-tests were used for quantitative variables to examine the difference between cancer and noncancer patients and between active and nonactive cancer patients. Kaplan-Meier survival curves were plotted, and the log rank test was used to compare in-hospital mortality between groups. Binary logistic regression analysis was used to evaluate predictors of ICU admission and mortality in COVID-19 patients. Results were reported as odds ratio (OR) and 95% CI and two-sided p-values <0.05 were set as significant. Mortality rate among patients admitted to the ICU was three times higher than those hospitalized in the general hospital floor (80.6 vs 19.4%, p < 0.001). In ward patients, 66.7% of deaths occurred within the first week, whereas in the ICU-admitted patients, higher death rate (60.7%) was remarkable in the second week. Most death in COVID-19 patients were attributed to ARDS (93.3%, p = 0.039). Regression analysis revealed that obesity (OR = 6.31, 95% CI = 1.81-22.1, p = 0.004), active smoking (OR = 6.15, 95% CI = 2.15-17.6, p = 0.001), CURB-65 score (OR = 2.76, 95% CI = 1.50-5.07, p = 0.001) and qSOFA score (OR = 2.57, 95% CI = 1.15-5.6, p = 0.021) were associated with an increased risk of mortality ( Figure 2 ). Characteristics of 57 cancer (30 men and 27 women) and 203 noncancer patients were compared. Their mean age was 63.6 ± 12.5 years and 58.7 ± 14.6 years, respectively (p = 0.023). Breast and prostate cancers were the most common ( Figure 3A ). There was no significant difference in severity scores between cancer and noncancer cohorts ( Figure 3B & C). As shown in Table 1 , the prevalence of chronic kidney disease was double in individuals with cancer (26.3 vs 13.3%, p = 0.025), and chest pain and fatigue were more common in the cancer group (p = 0.006 and 0.020, respectively). Despite being older and having a higher frequency of comorbidities, there was The comparison between active cancer patients with those who had a history of cancer showed no significant difference in their demographic and clinical features, laboratory data, complications or survival rate; however, active cancer cases required longer hospital stays (24.9 ± 17.1 vs 9.49 ± 6.39 days, p < 0.001) ( Table 3) . As depicted in Kaplan-Meier curves, there was no difference was observed in mortality between cancer and noncancer groups or between active and nonactive patients (Figure 4) . Data are presented as number (percentage) or mean ± SD. Fisher's exact or chi-square and Mann-Whitney or Student's t-tests were used, blood urea nitrogen level Ͼ19 mg/dl (Ͼ7 mmol/l), respiratory rate ≥30, blood pressure (systolic Ͻ90 mm Hg or diastolic ≤60 mm Hg) and age ≥65 years. ABG: Arterial blood gases; AKI: Acute kidney injury; ARDS: Acute respiratory distress syndrome; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; CURB-65: Confusion status; CVD: Cerebrovascular disease; ICU: Intensive care unit; LOS: length of stay; NLR: Neutrophil-to-lymphocyte ratio; P/F ratio: PaO2/FiO2 ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction); qSOFA: Quick Sequential Organ Failure Assessment; SD: Standard deviation. The COVID-19 pandemic has presented an incredible stress on the healthcare system. As of 5 September 2020, the total number of US COVID-19 infections had reached 6,095,007, with 185,687 deaths [15] . As the number of SARS-CoV-2 virus infections continues to rise, it has become increasingly important to characterize the disease process in varying patient populations for risk stratification. One highly vulnerable group is cancer patients, who tend to be hospitalized for a prolonged period, increasing their risk of exposure to COVID-19 [16] . They have a weakened immune system due to the cancer itself and treatments such as chemotherapy or radiotherapy that they are undergoing. The current study included 260 COVID-19 patients in whom 57 cancer patients were compared with 203 noncancer patients, with breast and prostate cancer cases being the most frequent. Our findings indicate that cancer patients diagnosed with COVID-19 do not have significantly different outcomes in terms of adverse events or mortality rates than noncancer patients infected with COVID-19. Discharged cancer patients, however, did have higher rates of comorbidities, increased frequency of reintubation and prolonged length of hospital stay compared with noncancer COVID-19 patients. In this study, cancer cohorts were older and more likely to have comorbid conditions. Similarly, different studies consistently reported that patients with a variety of comorbidities -including hypertension, diabetes and obesity -are at a higher risk of hospitalization due to COVID-19 than people without these conditions [17] . The data we compiled show a significantly higher number of comorbidities in cancer versus noncancer patients in both the deceased and discharged cohorts. In addition to underlying immunosuppression, the increased prevalence of comorbidities may be a contributing factor in the prolonged hospital stays seen in cancer patients relative to noncancer patients. In our cancer cohorts, despite being older and having a higher frequency of comorbidities, there was no significant difference in ICU admission or risk of developing complications in cancer patients. However, it did show significantly longer hospital stays and higher rates of reintubation in the cancer cohort. This is consistent with the more severe disease course for cancer patients with COVID-19, as elucidated in previous studies [18] [19] [20] [21] . It is also worth noting that active cancer patients experienced longer hospital stays than did either the nonactive cancer cohort or the noncancer group. Multivariable analysis, however, showed obesity, smoking and diabetes to be risk factors for unfavorable outcomes, consistent with prior studies [22, 23] . While our data show a trend toward survival in nonactive patients, they do not demonstrate a significant difference in mortality rates between cancer and noncancer patients or between active and nonactive cancer groups. According to a study conducted in the UK on cancer patients receiving anticancer therapy, the mortality appeared to be driven by age, gender and comorbidities [24] . It was also reported that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than previous radiation therapy or current anticancer treatment [25] . Due to the recent pandemic, there was a delay of patient management with decrease in encounters in multiple fields (e.g., cardiology, breast, ophthalmology, oncology) [4] . It was suggested to postpone the screening and management of some cancer patients to avoid the risk of COVID-19 infection [26] . Also, Maringe et al. postulated that a considerable increase in the number of avoidable cancer mortality in England is to be expected due to diagnostic delays due to the COVID-19 pandemic in the UK [27] . However, Sundriyal et al. showed that modified oncological practice measures such as tele-consultations and providing supportive care at or near home and involvement of local/family physicians should be considered to minimize inpatient admissions; however, day-care chemotherapies were continued to provide optimal oncology services [28] . More research is required to identify the at-risk population and the management of cancer patients during the COVID-19 pandemic to avoid unnecessary delays in management and provide patients with optimal care because delaying management can lead to poor outcomes [29] . There are several potential limitations to this study. This cohort of COVID-19 patients is representative of the patient population at two university hospitals in New Orleans, Louisiana. A nationwide study involving several regions and a larger patient cohort may provide a more representative population from which to can identify the correlation between COVID-19 and cancer. Also, patients in New Orleans have varying frequencies of comorbidities compared with the rest of the country, which could potentially skew the data reflecting adverse outcomes and mortality. Lastly, our paper distinguished between active and nonactive cancer patients but made no distinction in the treatment modalities for patients with active malignancy. Future studies should seek to characterize active cancer patients by treatment modality to determine the effects that anticancer therapies have on COVID-19 disease progression as well as any alterations that should be made in treatment modalities for these patients. While cancer patients stayed longer in the hospital there was with no difference in mortality among cancer patients and the non cancer patients with the Worse outcomes in COVID-19 appear to be driven by obesity as well as active smoking. This study will provide physicians and other healthcare workers valuable information regarding outcomes and anticipated clinical course for cancer patients diagnosed with COVID-19. As COVID-19 infection rates continue to remain high, it is our hope that this information will allow for better treatment and management of COVID-19 in patients with cancer. • Obesity, active smoking, diabetes and high Quick Sequential Organ Failure Assessment (qSOFA) score led to intensive care unit (ICU) admission. • Mortality rates among patients admitted to the ICU were three times higher than patients in the ward. • COVID-19 death was related mostly to acute respiratory distress syndrome. • Obesity, active smoking, diabetes and high qSOFA and CURB-65 (Confusion status, blood urea nitrogen level >19 mg/dl [>7 mmol/l], respiratory rate ≥30, blood pressure [systolic <90 mm Hg or diastolic ≤60 mm Hg] and age ≥65 years) scores were associated with an increased risk of mortality. • There was no significant difference in ICU admission between cancer and noncancer patients. • There was no significant difference in the rate of complication between cancer and noncancer patients. • Cohorts with cancer stayed longer in the hospital compared with noncancer patients. • No difference was observed in mortality between cancer and noncancer groups or between active and nonactive patients. CDC updates, expands list of people at risk of severe COVID-19 illness Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study Ethical considerations for treating cancer patients during the SARS-CoV-2 virus crisis: to treat or not to treat? A literature review and perspective from a cancer center in low-middle income country Early impact of COVID-19 outbreak on eye care: Insights from EUROCOVCAT group Ethical and practical considerations on cancer recommendations during COVID-19 pandemic Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Risk of COVID-19 for patients with cancer COVID-19 and cancer: lessons from a pooled meta-analysis Newyork State Department of Health The REDCap consortium: Building an international community of software platform partners Sequential oxygenation index and organ dysfunction assessment within the first 3 days of mechanical ventilation predict the outcome of adult patients with severe acute respiratory failure The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients Comparison of CRB-65 and quick sepsis-related organ failure assessment for predicting the need for intensive respiratory or vasopressor support in patients with COVID-19 External validation of the qSOFA score in emergency department patients with pneumonia WHO. WHO Coronavirus Disease (COVID-19) Dashboard, United States of America CDC updates, expands list of people at risk of severe COVID-19 illness COVID-19-associated hospitalization related to underlying medical conditions Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak COVID-19 and Cancer: a comprehensive review Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Comorbidity and its impact on patients with COVID-19. SN Compr COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area Cancer patient management during the COVID-19 pandemic The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study Impact of COVID-19 pandemic on oncology practices during nationwide lockdown period: a single centre experience and the way forward Delayed intravitreal anti-VEGF therapy for patients during the COVID-19 lockdown: an ethical endeavor The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.